Aquatic Capital Management LLC Acquires Shares of 24,083 CareDx, Inc (NASDAQ:CDNA)

Aquatic Capital Management LLC bought a new position in CareDx, Inc (NASDAQ:CDNA - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 24,083 shares of the company's stock, valued at approximately $516,000.

A number of other institutional investors have also recently made changes to their positions in CDNA. Sterling Capital Management LLC lifted its position in CareDx by 771.2% in the 4th quarter. Sterling Capital Management LLC now owns 1,272 shares of the company's stock valued at $27,000 after acquiring an additional 1,126 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in shares of CareDx by 553.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,922 shares of the company's stock worth $84,000 after purchasing an additional 3,322 shares during the last quarter. Plato Investment Management Ltd lifted its holdings in shares of CareDx by 34.1% during the fourth quarter. Plato Investment Management Ltd now owns 5,390 shares of the company's stock valued at $116,000 after purchasing an additional 1,370 shares in the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its position in shares of CareDx by 41.5% during the fourth quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 9,343 shares of the company's stock valued at $200,000 after buying an additional 2,742 shares during the last quarter. Finally, KLP Kapitalforvaltning AS bought a new stake in CareDx in the 4th quarter worth about $208,000.

Analyst Ratings Changes

A number of analysts have recently commented on CDNA shares. StockNews.com lowered shares of CareDx from a "buy" rating to a "hold" rating in a research note on Monday. Stephens reiterated an "overweight" rating and set a $40.00 target price on shares of CareDx in a research note on Monday. Wells Fargo & Company raised CareDx from an "underweight" rating to an "equal weight" rating and lowered their price target for the company from $28.00 to $24.00 in a report on Wednesday, January 15th. HC Wainwright reiterated a "neutral" rating and set a $25.00 price objective on shares of CareDx in a research report on Monday. Finally, The Goldman Sachs Group reduced their price target on shares of CareDx from $34.00 to $26.00 and set a "buy" rating for the company in a research report on Thursday, April 17th. Four research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $30.33.

Insider Transactions at CareDx

In other news, Director Peter Maag sold 13,281 shares of the firm's stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $17.23, for a total transaction of $228,831.63. Following the completion of the transaction, the director now owns 316,743 shares in the company, valued at $5,457,481.89. This trade represents a 4.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 4.90% of the company's stock.

CareDx Trading Up 1.0 %

CareDx stock traded up $0.15 during midday trading on Wednesday, hitting $14.33. The stock had a trading volume of 243,034 shares, compared to its average volume of 868,375. CareDx, Inc has a 52-week low of $9.99 and a 52-week high of $34.84. The company has a market capitalization of $797.80 million, a PE ratio of -5.31 and a beta of 2.27. The firm's fifty day moving average is $18.23 and its two-hundred day moving average is $21.31.

CareDx (NASDAQ:CDNA - Get Free Report) last issued its earnings results on Wednesday, April 30th. The company reported $0.09 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.03. The company had revenue of $84.69 million during the quarter, compared to the consensus estimate of $84.56 million. CareDx had a negative net margin of 45.90% and a negative return on equity of 53.70%. CareDx's quarterly revenue was up 17.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.03) EPS. As a group, equities research analysts predict that CareDx, Inc will post -0.9 earnings per share for the current fiscal year.

CareDx Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.